158 related articles for article (PubMed ID: 35645620)
1. Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis.
Benke M; Farkas N; Hegyi P; Tinusz B; Sarlós P; Erőss B; Szemes K; Vörhendi N; Szakács Z; Szücs Á
Pathol Oncol Res; 2022; 28():1610266. PubMed ID: 35645620
[No Abstract] [Full Text] [Related]
2. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
Maithel SK; Maloney S; Winston C; Gönen M; D'Angelica MI; Dematteo RP; Jarnagin WR; Brennan MF; Allen PJ
Ann Surg Oncol; 2008 Dec; 15(12):3512-20. PubMed ID: 18781364
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
[TBL] [Abstract][Full Text] [Related]
6. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
7. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
8. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.
Kiliç M; Göçmen E; Tez M; Ertan T; Keskek M; Koç M
Can J Surg; 2006 Aug; 49(4):241-4. PubMed ID: 16948881
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.
Zhang S; Wang YM; Sun CD; Lu Y; Wu LQ
World J Gastroenterol; 2008 Jun; 14(23):3750-3. PubMed ID: 18595144
[TBL] [Abstract][Full Text] [Related]
13. Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma.
Ahmad NA; Lewis JD; Siegelman ES; Rosato EF; Ginsberg GG; Kochman ML
Am J Gastroenterol; 2000 Aug; 95(8):1926-31. PubMed ID: 10950037
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.
Tamburrino D; Riviere D; Yaghoobi M; Davidson BR; Gurusamy KS
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD011515. PubMed ID: 27631326
[TBL] [Abstract][Full Text] [Related]
16. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
Xu B; Ding WX; Jin DY; Wang DS; Lou WH
World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
[TBL] [Abstract][Full Text] [Related]
17. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
18. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma.
Liu F; Wang JK; Ma WJ; Yang Q; Hu HJ; Li FY
ANZ J Surg; 2019 Mar; 89(3):E76-E80. PubMed ID: 30306702
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.
Hu HJ; Mao H; Tan YQ; Shrestha A; Ma WJ; Yang Q; Wang JK; Cheng NS; Li FY
Springerplus; 2016; 5():551. PubMed ID: 27190750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
